Literature DB >> 16956302

Immunosuppressive preconditioning or induction regimens : evidence to date.

Henkie P Tan1, Marc C Smaldone, Ron Shapiro.   

Abstract

The success of solid organ transplantation has been directly related to the development of immunosuppressive drug therapies. Preconditioning or induction therapy was developed to reduce early immunological and nonimmunological renal injury, with the goal of increasing long-term graft survival. However, the routine induction of immunological tolerance to solid organ allograft is currently not achievable because of the morbidity and mortality related to the immunosuppressive regimens themselves. The different therapeutic preconditioning or induction agents and their associated effects on cellular rejection, graft survival outcomes and the need for multiagent post-transplant maintenance therapy are reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956302     DOI: 10.2165/00003495-200666120-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  88 in total

1.  Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy.

Authors:  S John Swanson; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Linda C Cendales; Christine E Chamberlain; Shirley M Polly; David M Harlan; Allan D Kirk
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

2.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.

Authors:  D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

3.  Monoclonal antibodies in renal transplantation: old and new.

Authors:  Dirk R J Kuypers; Yves F C Vanrenterghem
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

4.  Pancreatic transplantation at the University of Pittsburgh.

Authors:  Ngoc L Thai; Kareem Abu-Elmagd; Akhar Khan; Geoffrey Bond; Amit Basu; Kusum Tom; George Mazariegos; Rakesh Sindhi; Jorge Reyes; Henkie P Tan; Amadeo Marcos; Thomas E Starzl; Ron Shapiro
Journal:  Clin Transpl       Date:  2004

5.  Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?

Authors:  J M Cecka; D Gjertson; P I Terasaki
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

6.  Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.

Authors:  Ron Shapiro; Demetrius Ellis; Henkie P Tan; Michael L Moritz; Amit Basu; Abhay N Vats; Akhtar S Khan; Edward A Gray; Adrianna Zeevi; Corde McFeaters; Gerri James; Mary Jo Grosso; Amadeo Marcos; Thomas E Starzl
Journal:  J Pediatr       Date:  2006-06       Impact factor: 4.406

7.  A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.

Authors:  Mark R Benfield; Amir Tejani; William E Harmon; Ruth McDonald; Donald M Stablein; Matthew McIntosh; Stephen Rose
Journal:  Pediatr Transplant       Date:  2005-06

Review 8.  Basiliximab: a review of its use as induction therapy in renal transplantation.

Authors:  Therese M Chapman; Gillian M Keating
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.

Authors:  Paul Keown; Robert Balshaw; Shideh Khorasheh; Mei Chong; Carlo Marra; Zoltan Kalo; Alex Korn
Journal:  BioDrugs       Date:  2003       Impact factor: 5.807

10.  Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

Authors:  A O Gaber; M R First; R J Tesi; R S Gaston; R Mendez; L L Mulloy; J A Light; L W Gaber; E Squiers; R J Taylor; J F Neylan; R W Steiner; S Knechtle; D J Norman; F Shihab; G Basadonna; D C Brennan; E E Hodge; B D Kahan; L Kahan; S Steinberg; E S Woodle; L Chan; J M Ham; T J Schroeder
Journal:  Transplantation       Date:  1998-07-15       Impact factor: 4.939

View more
  5 in total

1.  Immunodeficiency as a side effect of anabolic androgenic steroid abuse: a case of necrotizing myofasciitis.

Authors:  Giuseppe Bertozzi; Francesco Sessa; Francesca Maglietta; Luigi Cipolloni; Monica Salerno; Carmela Fiore; Palmira Fortarezza; Pietrantonio Ricci; Emanuela Turillazzi; Cristoforo Pomara
Journal:  Forensic Sci Med Pathol       Date:  2019-07-29       Impact factor: 2.007

Review 2.  Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.

Authors:  J Michael Tredger; Nigel W Brown; Anil Dhawan
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

Review 4.  Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview.

Authors:  Dela Golshayan; Manuel Pascual
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Secondary immunodeficiencies, including HIV infection.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12-29       Impact factor: 10.793

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.